PE20030336A1 - Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad - Google Patents
Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidadInfo
- Publication number
- PE20030336A1 PE20030336A1 PE2002000807A PE2002000807A PE20030336A1 PE 20030336 A1 PE20030336 A1 PE 20030336A1 PE 2002000807 A PE2002000807 A PE 2002000807A PE 2002000807 A PE2002000807 A PE 2002000807A PE 20030336 A1 PE20030336 A1 PE 20030336A1
- Authority
- PE
- Peru
- Prior art keywords
- indan
- ona
- alkyl
- chloro
- obesity
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 2
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 2
- -1 LEPTINE Chemical compound 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004890 diethylpropion Drugs 0.000 abstract 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002179 ephedrine Drugs 0.000 abstract 1
- XXVROGAVTTXONC-UHFFFAOYSA-N mefenorex Chemical compound ClCCCNC(C)CC1=CC=CC=C1 XXVROGAVTTXONC-UHFFFAOYSA-N 0.000 abstract 1
- 229960001468 mefenorex Drugs 0.000 abstract 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 abstract 1
- 229960000395 phenylpropanolamine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UTILIZACION DE COMPUESTOS INDAN-1-ONA SUSTITUIDOS EN C2 DE FORMULA I DONDE R1, R2, R3, R4 SON H, F, Cl, Br, I, CN, N3, NO2, OH, O-ALQUILO C1-C8, O-CICLOALQUILO C3-C8, O-CH2-FENILO, O-FENILO, O-CO-ALQUILO C1-C8, ENTRE OTROS; X ES S, SO, SO2, Y ES (CH2)p; p ES 0-3; R5 ES CF3, ALQUILO C1-C18, CICLOALQUILO C3-C8, (CH2)rCOR6, CH2-CH(NHR7)-COR8, FENILO, ; r ES 1-6; R6 ES OH, O-ALQUILO C1-C6, NH2, CH2-CH(NHR7)-COR8; R7 ES H, CO-ALQUILO C1-C4, COO-ALQUILO C1-C4; R8 ES OH, O-ALQUILO C1-C6, NH2 PARA LA PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE OBESIDAD. SON COMPUESTOS PREFERIDOS 5-CLORO-2-METILSULFANIL-INDAN-1-ONA; 5-CLORO-2-METANOSULFONIL-INDAN-1-ONA; 5-CLORO-2-FENILSULFANIL-INDAN-1-ONA, 2-BENCENOSULFONIL-5-CLORO-INDAN-1-ONA, 5-CLORO-2-METANOSULFONIL-INDAN-1-ONA. TAMBIEN SE REFIERE AL USO CON CATINA, FENILPROPANOLAMINA, AMFEPRAMONA, MEFENOREX, EFEDRINA, LEPTINA, DEXANFETAMINA, ANFETAMINA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10142668A DE10142668A1 (de) | 2001-08-31 | 2001-08-31 | Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030336A1 true PE20030336A1 (es) | 2003-05-19 |
Family
ID=7697238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000807A PE20030336A1 (es) | 2001-08-31 | 2002-08-22 | Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6946492B2 (es) |
| EP (1) | EP1424999A1 (es) |
| JP (1) | JP4342306B2 (es) |
| AU (1) | AU2002336985B2 (es) |
| CA (1) | CA2458555A1 (es) |
| DE (1) | DE10142668A1 (es) |
| IL (2) | IL160607A0 (es) |
| MX (1) | MXPA04001853A (es) |
| PE (1) | PE20030336A1 (es) |
| WO (1) | WO2003020256A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010206549B2 (en) * | 2009-01-26 | 2016-08-25 | Dcb-Usa, Llc | Use of pterosin compounds for treating diabetes and obesity |
| CN103333144B (zh) * | 2013-06-17 | 2014-12-10 | 温州大学 | 一种2-硫基-3-卤代苯并呋喃化合物及其合成方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0009554B1 (de) * | 1978-07-27 | 1983-04-27 | Schering Aktiengesellschaft | Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
| RU2073673C1 (ru) * | 1987-10-19 | 1997-02-20 | Пфайзер Инк. | Рацемические и оптические активные производные тетралина и 7-гидрокситетралина |
| IL124756A0 (en) * | 1995-12-06 | 1999-01-26 | Venantius Limited | Indane dimer compounds and their pharmaceutical use |
| WO1997026265A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
| IL127296A (en) | 1996-12-31 | 2003-01-12 | Reddy Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| HUP0003999A3 (en) | 1997-07-16 | 2003-03-28 | Novo Nordisk As | Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| DE60012700T2 (de) * | 1999-03-01 | 2005-07-28 | Pfizer Products Inc., Groton | Oxamsäure und deren derivate als liganden der thyroid-rezeptoren |
| FR2796070B1 (fr) * | 1999-07-06 | 2003-02-21 | Lipha | Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation |
| EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
-
2001
- 2001-08-31 DE DE10142668A patent/DE10142668A1/de not_active Withdrawn
-
2002
- 2002-08-17 CA CA002458555A patent/CA2458555A1/en not_active Abandoned
- 2002-08-17 MX MXPA04001853A patent/MXPA04001853A/es active IP Right Grant
- 2002-08-17 JP JP2003524565A patent/JP4342306B2/ja not_active Expired - Fee Related
- 2002-08-17 AU AU2002336985A patent/AU2002336985B2/en not_active Ceased
- 2002-08-17 EP EP02772166A patent/EP1424999A1/de not_active Withdrawn
- 2002-08-17 IL IL16060702A patent/IL160607A0/xx active IP Right Grant
- 2002-08-17 WO PCT/EP2002/009208 patent/WO2003020256A1/de active Application Filing
- 2002-08-22 PE PE2002000807A patent/PE20030336A1/es not_active Application Discontinuation
- 2002-08-30 US US10/231,162 patent/US6946492B2/en not_active Expired - Fee Related
-
2004
- 2004-02-26 IL IL160607A patent/IL160607A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2458555A1 (en) | 2003-03-13 |
| IL160607A (en) | 2011-03-31 |
| AU2002336985B2 (en) | 2006-11-16 |
| US20030134882A1 (en) | 2003-07-17 |
| MXPA04001853A (es) | 2004-06-15 |
| DE10142668A1 (de) | 2003-03-20 |
| US6946492B2 (en) | 2005-09-20 |
| IL160607A0 (en) | 2004-07-25 |
| JP2005503396A (ja) | 2005-02-03 |
| WO2003020256A1 (de) | 2003-03-13 |
| JP4342306B2 (ja) | 2009-10-14 |
| EP1424999A1 (de) | 2004-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021091A1 (es) | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion | |
| RU2370485C2 (ru) | Амидоацетонитрильные производные | |
| PE20050142A1 (es) | 2-hidroxi-3-diaminoalcanos de benzamida | |
| PE20050476A1 (es) | Compuestos de pirrol y pirazol | |
| ATE381540T1 (de) | Oximesther-fotoinitiatoren | |
| AR039789A1 (es) | Pirazolopiridinas sustituidas con carbamato | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| UY27699A1 (es) | Inhibidores. | |
| BRPI0606318B8 (pt) | composto, composição, e, uso de um composto | |
| PE20071328A1 (es) | Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso | |
| WO2003016291A1 (fr) | Activateur du recepteur $g(d) sensible au proliferateur de peroxysome | |
| CO5611123A2 (es) | Cumarinas utiles como biomarcadores | |
| BR0311693A (pt) | Sal de formato de o-desmetil-venlafaxina | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| CO5140075A1 (es) | Agentes terapeuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| DE60312136D1 (de) | Radiofluorierungsverfahren | |
| CO5700735A2 (es) | Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas | |
| IN2012DN02546A (es) | ||
| PE20030336A1 (es) | Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad | |
| PE20030363A1 (es) | Utilizacion de sistemas de indan-1-ol varias veces sustituidos, para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad | |
| RU2009138470A (ru) | Композиция для наружного применения на коже | |
| PE20030339A1 (es) | Derivados de sistemas de indan-1-oles sustituidos en c2 y procedimiento para su preparacion | |
| AR035481A1 (es) | Compuestos de benzosultamoxazolidinona, una composicion farmaceutica, y el uso de dichos compuestos para la manufactura de medicamentos antibacterianos | |
| DE50008450D1 (de) | Verfahren zur Herstellung von 2-Aminomethyl-1,4-diamino-benzol und dessen Salzen | |
| PE20030362A1 (es) | Sistemas de indan-1-ol-sustituidos en c2 y procedimiento para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |